SARS‐CoV‐2 antibody kinetics in blood donors with a previously positive SARS‐CoV‐2 antibody test within a seroprevalence survey
The persistence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies is a matter of importance regarding the coronavirus disease 19 (COVID‐19) pandemic. To observe antibody dynamics, 105 blood donors, positive for SARS‐CoV‐2 antibodies by a lateral flow test within a seropreval...
Saved in:
| Published in: | Journal of medical virology Vol. 94; no. 4; pp. 1711 - 1716 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Wiley Subscription Services, Inc
01.04.2022
John Wiley and Sons Inc |
| Subjects: | |
| ISSN: | 0146-6615, 1096-9071, 1096-9071 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The persistence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies is a matter of importance regarding the coronavirus disease 19 (COVID‐19) pandemic. To observe antibody dynamics, 105 blood donors, positive for SARS‐CoV‐2 antibodies by a lateral flow test within a seroprevalence study, were included in this study. Thirty‐nine (37%) of 105 the donors were confirmed positive by a total Ig Wantai enzyme‐linked immunosorbent assay (ELISA). Three (8%) in this group of 39 reported severe and 26/39 (67%) mild to moderate COVID‐19 symptoms. By further ELISA‐testing, 33/39 (85%) donors were initially positive for IgG antibodies, 31/39 (79%) for IgA, and 32/39 (82%) for IgM, while 27/39 (69%) were positive for all three isotypes. Persistence of IgG, IgA, and IgM was observed in 73%, 79%, and 32% of donors, respectively, after 6–9 months of observation. For IgM antibodies, the decline in the proportion of positive donors was statistically significant (p = 0.002) during 12 months observation, for IgG only the decline at 3 months was statistically significant (p = 0.042). Four donors exhibited notable increases in antibody levels. In conclusion, persistent SARS‐CoV‐2 IgA antibodies and IgG antibodies at 6–9 months are present in approximately three of four individuals with previous mild to moderate COVID‐19. |
|---|---|
| AbstractList | The persistence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies is a matter of importance regarding the coronavirus disease 19 (COVID‐19) pandemic. To observe antibody dynamics, 105 blood donors, positive for SARS‐CoV‐2 antibodies by a lateral flow test within a seroprevalence study, were included in this study. Thirty‐nine (37%) of 105 the donors were confirmed positive by a total Ig Wantai enzyme‐linked immunosorbent assay (ELISA). Three (8%) in this group of 39 reported severe and 26/39 (67%) mild to moderate COVID‐19 symptoms. By further ELISA‐testing, 33/39 (85%) donors were initially positive for IgG antibodies, 31/39 (79%) for IgA, and 32/39 (82%) for IgM, while 27/39 (69%) were positive for all three isotypes. Persistence of IgG, IgA, and IgM was observed in 73%, 79%, and 32% of donors, respectively, after 6–9 months of observation. For IgM antibodies, the decline in the proportion of positive donors was statistically significant (p = 0.002) during 12 months observation, for IgG only the decline at 3 months was statistically significant (p = 0.042). Four donors exhibited notable increases in antibody levels. In conclusion, persistent SARS‐CoV‐2 IgA antibodies and IgG antibodies at 6–9 months are present in approximately three of four individuals with previous mild to moderate COVID‐19. The persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies is a matter of importance regarding the coronavirus disease 19 (COVID-19) pandemic. To observe antibody dynamics, 105 blood donors, positive for SARS-CoV-2 antibodies by a lateral flow test within a seroprevalence study, were included in this study. Thirty-nine (37%) of 105 the donors were confirmed positive by a total Ig Wantai enzyme-linked immunosorbent assay (ELISA). Three (8%) in this group of 39 reported severe and 26/39 (67%) mild to moderate COVID-19 symptoms. By further ELISA-testing, 33/39 (85%) donors were initially positive for IgG antibodies, 31/39 (79%) for IgA, and 32/39 (82%) for IgM, while 27/39 (69%) were positive for all three isotypes. Persistence of IgG, IgA, and IgM was observed in 73%, 79%, and 32% of donors, respectively, after 6-9 months of observation. For IgM antibodies, the decline in the proportion of positive donors was statistically significant (p = 0.002) during 12 months observation, for IgG only the decline at 3 months was statistically significant (p = 0.042). Four donors exhibited notable increases in antibody levels. In conclusion, persistent SARS-CoV-2 IgA antibodies and IgG antibodies at 6-9 months are present in approximately three of four individuals with previous mild to moderate COVID-19.The persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies is a matter of importance regarding the coronavirus disease 19 (COVID-19) pandemic. To observe antibody dynamics, 105 blood donors, positive for SARS-CoV-2 antibodies by a lateral flow test within a seroprevalence study, were included in this study. Thirty-nine (37%) of 105 the donors were confirmed positive by a total Ig Wantai enzyme-linked immunosorbent assay (ELISA). Three (8%) in this group of 39 reported severe and 26/39 (67%) mild to moderate COVID-19 symptoms. By further ELISA-testing, 33/39 (85%) donors were initially positive for IgG antibodies, 31/39 (79%) for IgA, and 32/39 (82%) for IgM, while 27/39 (69%) were positive for all three isotypes. Persistence of IgG, IgA, and IgM was observed in 73%, 79%, and 32% of donors, respectively, after 6-9 months of observation. For IgM antibodies, the decline in the proportion of positive donors was statistically significant (p = 0.002) during 12 months observation, for IgG only the decline at 3 months was statistically significant (p = 0.042). Four donors exhibited notable increases in antibody levels. In conclusion, persistent SARS-CoV-2 IgA antibodies and IgG antibodies at 6-9 months are present in approximately three of four individuals with previous mild to moderate COVID-19. The persistence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies is a matter of importance regarding the coronavirus disease 19 (COVID‐19) pandemic. To observe antibody dynamics, 105 blood donors, positive for SARS‐CoV‐2 antibodies by a lateral flow test within a seroprevalence study, were included in this study. Thirty‐nine (37%) of 105 the donors were confirmed positive by a total Ig Wantai enzyme‐linked immunosorbent assay (ELISA). Three (8%) in this group of 39 reported severe and 26/39 (67%) mild to moderate COVID‐19 symptoms. By further ELISA‐testing, 33/39 (85%) donors were initially positive for IgG antibodies, 31/39 (79%) for IgA, and 32/39 (82%) for IgM, while 27/39 (69%) were positive for all three isotypes. Persistence of IgG, IgA, and IgM was observed in 73%, 79%, and 32% of donors, respectively, after 6–9 months of observation. For IgM antibodies, the decline in the proportion of positive donors was statistically significant ( p = 0.002) during 12 months observation, for IgG only the decline at 3 months was statistically significant ( p = 0.042). Four donors exhibited notable increases in antibody levels. In conclusion, persistent SARS‐CoV‐2 IgA antibodies and IgG antibodies at 6–9 months are present in approximately three of four individuals with previous mild to moderate COVID‐19. |
| Author | Bauer, Joschka M. Jensen, Iben S. Sprogøe, Ulrik Nilsson, Anna C. Levring, Mette B. Rasmussen, Line D. Davidsen, Jesper R. Holm, Dorte K. Lillevang, Søren T. |
| AuthorAffiliation | 2 Department of Clinical Research University of Southern Denmark Odense Denmark 4 Department of Infectious Diseases Odense University Hospital Odense Denmark 1 Department of Clinical Immunology Odense University Hospital Odense Denmark 3 Department of Respiratory Medicine Odense University Hospital Odense Denmark |
| AuthorAffiliation_xml | – name: 3 Department of Respiratory Medicine Odense University Hospital Odense Denmark – name: 2 Department of Clinical Research University of Southern Denmark Odense Denmark – name: 4 Department of Infectious Diseases Odense University Hospital Odense Denmark – name: 1 Department of Clinical Immunology Odense University Hospital Odense Denmark |
| Author_xml | – sequence: 1 givenname: Mette B. orcidid: 0000-0002-4366-382X surname: Levring fullname: Levring, Mette B. email: mette.boegh.levring@rsyd.dk organization: Odense University Hospital – sequence: 2 givenname: Dorte K. surname: Holm fullname: Holm, Dorte K. organization: Odense University Hospital – sequence: 3 givenname: Anna C. surname: Nilsson fullname: Nilsson, Anna C. organization: Odense University Hospital – sequence: 4 givenname: Joschka M. surname: Bauer fullname: Bauer, Joschka M. organization: Odense University Hospital – sequence: 5 givenname: Iben S. surname: Jensen fullname: Jensen, Iben S. organization: Odense University Hospital – sequence: 6 givenname: Jesper R. surname: Davidsen fullname: Davidsen, Jesper R. organization: Odense University Hospital – sequence: 7 givenname: Line D. surname: Rasmussen fullname: Rasmussen, Line D. organization: Odense University Hospital – sequence: 8 givenname: Ulrik surname: Sprogøe fullname: Sprogøe, Ulrik organization: Odense University Hospital – sequence: 9 givenname: Søren T. surname: Lillevang fullname: Lillevang, Søren T. organization: Odense University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34845745$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kcFu1DAURS1URKeFBT-ALLGBRVrbcZx4g1SNgLYqQqLQreVxXqiHjD3YTqrs2LHtN_IleDqlgkplYy987vW77-6hHecdIPSckgNKCDtcrsYDVvNGPEIzSqQoJKnpDpoRykUhBK120V6MS0JIIxl7gnZL3vCq5tUM_Tw_-nT-68f13F_kk2Htkl34dsLfrINkTcTW4UXvfYtb73yI-MqmS6zxOsBo_RD7Ca99tMmOgB_yShDTjS57aRwh-I1a9-AM4DiEEaan6HGn-wjPbu999OXd28_z4-Ls4_uT-dFZYXhNRQFlBS2vNGFlSaWpy5y67RpjeNeUVPAWDGEdq1tRASu5FFTLii5Iw5jWTVuX--jN1nc9LFbQGnAp6F6tg13pMCmvrfr3xdlL9dWPShJa5T-zwatbg-C_DzmYWtlooO-1g7wOxQTheRRai4y-vIcu_RBcjpcpJgkTsqky9eLvie5G-dNRBl5vARN8jAG6O4QStelf5f7VTf-ZPbzHGpt0sn4Txvb_U1zZHqaHrdXph4ut4jdMJcZN |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0267102 crossref_primary_10_3389_fimmu_2023_1152522 crossref_primary_10_1186_s12879_023_08829_1 crossref_primary_10_1155_2022_9342680 |
| Cites_doi | 10.3389/fcimb.2021.559447 10.1371/journal.pone.0248946 10.1016/S0140-6736(21)00575-4 10.1093/clinchem/hvaa211 10.1080/23744235.2020.1871066 10.1016/j.xcrm.2021.100222 10.1016/j.ijid.2020.12.017 10.1016/S2666-5247(21)00025-2 10.1128/JCM.01361-20 10.1111/imm.13262 |
| ContentType | Journal Article |
| Copyright | 2021 Wiley Periodicals LLC 2021 Wiley Periodicals LLC. 2022 Wiley Periodicals LLC |
| Copyright_xml | – notice: 2021 Wiley Periodicals LLC – notice: 2021 Wiley Periodicals LLC. – notice: 2022 Wiley Periodicals LLC |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7TK 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 5PM |
| DOI | 10.1002/jmv.27486 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Virology and AIDS Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | Genetics Abstracts MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | LEVRING et al |
| EISSN | 1096-9071 |
| EndPage | 1716 |
| ExternalDocumentID | PMC9015331 34845745 10_1002_jmv_27486 JMV27486 |
| Genre | shortCommunication Journal Article |
| GeographicLocations | Denmark |
| GeographicLocations_xml | – name: Denmark |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3O- 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS ECGQY EJD ELTNK EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E VH1 W8V W99 WBKPD WHG WIB WIH WIJ WIK WJL WNSPC WOHZO WQJ WRC WUP WXI WXSBR WYISQ X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~KM ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION O8X CGR CUY CVF ECM EIF NPM 7QL 7TK 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 5PM |
| ID | FETCH-LOGICAL-c4716-e35ed45a023319c73748df8cc4f83164dec02f27d65e234961a951b0822aa8d73 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 6 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000730331700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0146-6615 1096-9071 |
| IngestDate | Tue Nov 04 01:58:02 EST 2025 Fri Jul 11 09:01:08 EDT 2025 Sat Nov 29 14:36:16 EST 2025 Thu Apr 03 06:59:50 EDT 2025 Sat Nov 29 03:40:48 EST 2025 Tue Nov 18 20:52:20 EST 2025 Wed Jan 22 16:27:15 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | COVID-19 blood donors SARS-CoV-2 antibody lateral flow test |
| Language | English |
| License | 2021 Wiley Periodicals LLC. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4716-e35ed45a023319c73748df8cc4f83164dec02f27d65e234961a951b0822aa8d73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-4366-382X |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9015331 |
| PMID | 34845745 |
| PQID | 2629026985 |
| PQPubID | 105515 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9015331 proquest_miscellaneous_2604831176 proquest_journals_2629026985 pubmed_primary_34845745 crossref_primary_10_1002_jmv_27486 crossref_citationtrail_10_1002_jmv_27486 wiley_primary_10_1002_jmv_27486_JMV27486 |
| PublicationCentury | 2000 |
| PublicationDate | April 2022 |
| PublicationDateYYYYMMDD | 2022-04-01 |
| PublicationDate_xml | – month: 04 year: 2022 text: April 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: London – name: Hoboken |
| PublicationTitle | Journal of medical virology |
| PublicationTitleAlternate | J Med Virol |
| PublicationYear | 2022 |
| Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
| References | 2021; 16 2021; 162 2020; 58 2021; 53 2020; 66 2021; 397 2021; 2 2021; 11 2021; 103 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_9_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 |
| References_xml | – volume: 53 start-page: 315 issue: 5 year: 2021 end-page: 324 article-title: A systematic review on the recurrence of SARS‐CoV‐2 virus: frequency, risk factors, and possible explanations publication-title: Infect Dis (Lond) – volume: 16 issue: 4 year: 2021 article-title: Comparison of seroprevalence of SARS‐CoV‐2 infections with cumulative and imputed COVID‐19 cases: Systematic review publication-title: PLoS One – volume: 66 start-page: 1538 issue: 12 year: 2020 end-page: 1547 article-title: Association between SARS‐CoV‐2 neutralizing antibodies and commercial serological assays publication-title: Clin Chem – volume: 2 start-page: e240 issue: 6 year: 2021 end-page: e249 article-title: Dynamics of SARS‐CoV‐2 neutralising antibody responses and duration of immunity: a longitudinal study publication-title: Lancet Microbe. – volume: 58 start-page: 1 issue: 10 year: 2020 end-page: 12 article-title: Evaluation of six commercial mid‐ to high‐volume antibody and six point‐of‐care lateral flow assays for detection of SARS‐CoV‐2 antibodies publication-title: J Clin Microbiol – volume: 162 start-page: 30 issue: 1 year: 2021 end-page: 43 article-title: T‐cell responses and therapies against SARS‐CoV‐2 infection publication-title: Immunology – volume: 11 year: 2021 article-title: Severe acute respiratory syndrome coronavirus 2 viral RNA load status and antibody distribution among patients and asymptomatic carriers in Central China publication-title: Front Cell Infect Microbiol – volume: 2 issue: 3 year: 2021 article-title: Low awareness of past SARS‐CoV‐2 infection in healthy plasma donors publication-title: Cell Rep Med. – volume: 103 start-page: 381 year: 2021 end-page: 388 article-title: Comparison of six commercially available SARS‐CoV‐2 antibody assays‐choice of assay depends on intended use publication-title: Int J Infect Dis – volume: 397 start-page: 1204 issue: 10280 year: 2021 end-page: 1212 article-title: Assessment of protection against reinfection with SARS‐CoV‐2 among 4 million PCR‐tested individuals in Denmark in 2020: a population‐level observational study publication-title: Lancet – ident: e_1_2_9_5_1 doi: 10.3389/fcimb.2021.559447 – ident: e_1_2_9_3_1 doi: 10.1371/journal.pone.0248946 – ident: e_1_2_9_8_1 doi: 10.1016/S0140-6736(21)00575-4 – ident: e_1_2_9_4_1 doi: 10.1093/clinchem/hvaa211 – ident: e_1_2_9_9_1 doi: 10.1080/23744235.2020.1871066 – ident: e_1_2_9_2_1 doi: 10.1016/j.xcrm.2021.100222 – ident: e_1_2_9_6_1 doi: 10.1016/j.ijid.2020.12.017 – ident: e_1_2_9_7_1 doi: 10.1016/S2666-5247(21)00025-2 – ident: e_1_2_9_10_1 doi: 10.1128/JCM.01361-20 – ident: e_1_2_9_11_1 doi: 10.1111/imm.13262 |
| SSID | ssj0008922 |
| Score | 2.3877358 |
| Snippet | The persistence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies is a matter of importance regarding the coronavirus disease 19... The persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies is a matter of importance regarding the coronavirus disease 19... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1711 |
| SubjectTerms | Adult Antibodies Antibodies, Viral - blood antibody Blood Blood donors Blood Donors - statistics & numerical data Coronaviruses COVID-19 COVID-19 - blood COVID-19 - epidemiology COVID-19 - immunology Denmark - epidemiology Enzyme-linked immunosorbent assay Female Humans Immunoglobulin A Immunoglobulin A - blood Immunoglobulin G Immunoglobulin G - blood Immunoglobulin M Immunoglobulin M - blood Isotypes Kinetics lateral flow test Male Pandemics Reinfection - blood Reinfection - epidemiology Reinfection - immunology SARS-CoV-2 - immunology SARS‐CoV‐2 Seroepidemiologic Studies Serology Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Severity of Illness Index Short Communication Signs and symptoms Statistical analysis Viral diseases Virology Young Adult |
| Title | SARS‐CoV‐2 antibody kinetics in blood donors with a previously positive SARS‐CoV‐2 antibody test within a seroprevalence survey |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.27486 https://www.ncbi.nlm.nih.gov/pubmed/34845745 https://www.proquest.com/docview/2629026985 https://www.proquest.com/docview/2604831176 https://pubmed.ncbi.nlm.nih.gov/PMC9015331 |
| Volume | 94 |
| WOSCitedRecordID | wos000730331700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1096-9071 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008922 issn: 0146-6615 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB7BUlW9tNDnthSZqodeUjaOEzvihKCrqgJUQUF7i_yKukATtNldaW-99cpv5JcwdrKBFUWq1EsUyWPHGc94ZuzxZ4CPSSikiSgPDFrzgGmMWZWiSZBbLrnOqezVOLP7_PBQDAbp9yXYnp-FqfEh2gU3pxl-vnYKLlW1dQsaevZr-hlDKpEswwpFuY07sLJ31D_ZbydikdabCDgZBGiG4jmwUI9utZUXzdE9H_N-quRdF9bboP6z_-r9KjxtXE-yU8vKGizZ4jk8Pmg211_An-Odo-Pr31e75Sk-KUGeD1VpZuQcix2aMxkWxCe6E1MW5agibhGXSHLpUoXLSXUxI3UO2NSSh9pCz3bs62FbkqD8u1tYUNrdBEOqyWhqZy_hpP_lx-7XoLmnIdBo2pLARrE1LMZhjVChNXeINiYXWrNcRBiOGat7NKfcJLGlDqA-lOjXKYc1L6UwPHoFnaIs7BsgikXMqJ5Gv0kxg9FOwniaGBMKrdBXyrvwaT5cmW5AzN1dGhdZDb9MM2Rs5hnbhQ8t6WWN3PE3ovX5mGeN8lYZTWiKoWkq4i5stsWodm4vRRYWGYo0Dos_DDk28boWkfYrERMs5gxr8wXhaQkcpPdiSTH86aG9nXeGTMTf9MLzcMezbwen_uXtv5O-gyfUHd7weUfr0BmPJvY9PNLT8bAabcAyH4iNRoduAHIpJEc |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VFkEvpbzabUsxiAOX0I3jxI7US1VYFdhdob7UW-TYjrp9JNVmd6W99caV38gvYexkA6tSCYlLFMljxxnPeGbs8WeAd5EvpA4o9zRac48pjFnTlEZeZrjkKqOyXeHMdnm_L87O4m8LsDs7C1PhQzQLblYz3HxtFdwuSO_8Rg29uJ58wJhKRA9giaEYoXwvfTzsnHSbmVjE1S4CzgYe2qFwhizUpjtN5Xl7dMfJvJsr-acP64xQ58n_dX8VVmrnk-xV0vIUFkz-DB716u315_D9aO_w6Oftj_3iFJ-UINcHaaGn5BKLLZ4zGeTEpboTXeTFsCR2GZdIcmOThYtxeTUlVRbYxJD72kLfduTqYVuSoAbYe1hQ3u0UQ8rxcGKmL-Ck8-l4_8Crb2rwFBq3yDNBaDQLcWADVGnFLaaNzoRSLBMBBmTaqDbNKNdRaKiFqPclenapRZuXUmgevITFvMjNOpCUBUynbYWeU8o0xjsR43GktS9Uit5S1oL3s_FKVA1jbm_TuEoqAGaaIGMTx9gWvG1Ibyrsjr8Rbc0GPanVt0xoRGMMTmMRtuBNU4yKZ3dTZG6QoUhj0fh9n2MTa5WMNF8JmGAhZ1ibz0lPQ2BBvedL8sG5A_e2_hkyEX_TSc_9HU--9E7dy8a_k76GxwfHvW7S_dz_ugnL1B7lcFlIW7A4Go7NK3ioJqNBOdyuVekX7ZInTw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB7RpUK90Cd0y6Nu1UMvgY3jxI7UC4Ku-lhWCAriFjm2I7aFZLXZXWlvvXHtb-wvYexkU1YUqVIvUSSPHWc845mxx58B3kW-kDqg3NNozT2mMGZNUxp5meGSq4zKToUz2-P9vjg_j4-W4MP8LEyFD9EsuFnNcPO1VXAz1NnuH9TQ71fTHYypRPQAlpm9RKYFywfH3dNeMxOLuNpFwNnAQzsUzpGFOnS3qbxoj-44mXdzJW_7sM4IdR__X_efwGrtfJK9SlqewpLJn8HKYb29_hyuT_aOT37__LVfnOGTEuT6IC30jPzAYovnTAY5canuRBd5MSqJXcYlkgxtsnAxKS9npMoCmxpyX1vo245dPWxLEtQAew8LyrudYkg5GU3N7AWcdj9-2__k1Tc1eAqNW-SZIDSahTiwAaq04hbTRmdCKZaJAAMybVSHZpTrKDTUQtT7Ej271KLNSyk0D9aglRe5eQkkZQHTaUeh55QyjfFOxHgcae0LlaK3lLXh_Xy8ElXDmNvbNC6TCoCZJsjYxDG2DW8b0mGF3fE3os35oCe1-pYJjWiMwWkswja8aYpR8exuiswNMhRpLBq_73NsYr2SkeYrARMs5Axr8wXpaQgsqPdiST64cODe1j9DJuJvOum5v-PJl8Mz9_Lq30lfw8rRQTfpfe5_3YBH1J7kcElIm9AajyZmCx6q6XhQjrZrTboBQwsmyg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS%E2%80%90CoV%E2%80%902+antibody+kinetics+in+blood+donors+with+a+previously+positive+SARS%E2%80%90CoV%E2%80%902+antibody+test+within+a+seroprevalence+survey&rft.jtitle=Journal+of+medical+virology&rft.au=Levring%2C+Mette+B.&rft.au=Holm%2C+Dorte+K.&rft.au=Nilsson%2C+Anna+C.&rft.au=Bauer%2C+Joschka+M.&rft.date=2022-04-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=0146-6615&rft.eissn=1096-9071&rft.volume=94&rft.issue=4&rft.spage=1711&rft.epage=1716&rft_id=info:doi/10.1002%2Fjmv.27486&rft_id=info%3Apmid%2F34845745&rft.externalDocID=PMC9015331 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon |